Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

2009 ◽  
Vol 9 (2) ◽  
pp. 77-85 ◽  
Author(s):  
Adam M. Brufsky ◽  
Linda D. Bosserman ◽  
Richard R. Caradonna ◽  
Barbara B. Haley ◽  
C. Michael Jones ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Aromatase Inhibitor ◽  
Postmenopausal Women ◽  
Early Breast Cancer

The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: 36-month follow-up.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e11111-e11111 ◽  
Author(s):  
J. Greenberg ◽  
S. M. Stemmer ◽  
R. Bernstein-Molho ◽  
S. Pelles-Avraham ◽  
I. Stephansky ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Protective Effect ◽  
Postmenopausal Women ◽  
Early Breast Cancer

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

Cancer ◽  
2008 ◽  
Vol 112 (5) ◽  
pp. 1001-1010 ◽  
Author(s):  
Nigel J. Bundred ◽  
Ian D. Campbell ◽  
Neville Davidson ◽  
Richard H. DeBoer ◽  
Holger Eidtmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Aromatase Inhibitor ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Effective Inhibition
Sign in / Sign up

Export Citation Format

Share Document